Form 4: Lucid Diagnostics Director James L. Cox Receives Restricted Stock Grant

Director James L. Cox of Lucid Diagnostics Inc. reports the acquisition of 112,800 shares of restricted stock with a vesting date in 2028.

Summary

• James L. Cox, a director of Lucid Diagnostics Inc., filed a Form 4 indicating a transaction involving the company's securities.
• On February 20, 2025, Cox acquired 112,800 shares of common stock.
• These shares were granted as restricted stock under the Issuer's 2018 Equity Plan.
• The restricted stock has a single vesting date of May 20, 2028, and is subject to forfeiture if the required service period isn't completed.
• Following the transaction, Cox directly owns 282,120 shares of Lucid Diagnostics Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of restricted stock to a director is a common practice and can be seen as a sign of alignment between management and shareholders.

Positives

• The acquisition of restricted stock by a director could signal confidence in the company's future performance.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could be a risk if Cox leaves the company before the vesting date.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the restricted stock in 2028 suggests a long-term commitment from the director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for investor confidence.

Key Dates

Keywords

Form 4, Lucid Diagnostics, Director, James L. Cox, Restricted Stock, Equity Plan, Beneficial Ownership, Securities